Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bad Bevensen

3 clinical trials in Bad Bevensen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bevensen at a glance
3
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

3 trials in Bad Bevensen

Open in trial search

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Hypertension

Recruiting

Study of Dapagliflozin for Reducing Cardiovascular Events in Adults with High Blood Pressure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Pulmonary hypertension

Not yet recruiting

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Levosimendan
  • Sponsor:Tenax Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bad Bevensen

What the registry says about research in the country

01 Cardiovascular Disease Trials

In Bad Bevensen, Germany, two actively recruiting studies focus on cardiovascular diseases. With a single research site and investigator, the trials target arterial hypertension and atherosclerotic cardiovascular disease, aiming to lower major adverse cardiovascular outcomes.

  • Evaluation of AZD0780 versus placebo on MACE‑PLUS events
  • Assessment of adding an SGLT2 inhibitor to standard antihypertensive therapy
  • Exploration of composite endpoints including cardiovascular death, myocardial infarction, ischemic stroke, and renal complications
  • Investigation of treatment impact on major limb ischemia and urgent arterial revascularisation

Both projects seek to identify more effective strategies for preventing heart attacks, strokes, and related vascular complications, potentially shaping future guidelines.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.